pharma-and-clinical-pharmacy-congress-2016_posters

5 / 21

Notes:
Page 55
Pharma & Clinical Pharmacy Congress 2016
November 07-09, 2016
Volume 5 Issue 4(Suppl) Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal
conferenceseries .com
November 07-09, 2016 Las Vegas, Nevada, USA
4th International
Pharma & Clinical Pharmacy Congress
Mei Zhan, Clin Pharmacol Biopharm 2016, 5:4(Suppl)
Cost-effectiveness analysis of additional Bevacizumab to chemotherapy for malignant pleural
mesothelioma from a Chinese perspective
Mei Zhan
West China Hospital, China
Objective: To evaluate the cost-effectiveness of addition of bevacizumab to pemetrexed plus cisplatin (PC) for malignant pleural
mesothelioma (MPM) following a phase III trial that show an overall survival (OS) benefit with the addition of bevacizumab.
Methods: A Markov decision tree based on the mesothelioma avastin cisplatin pemetrexed study (MAPS) was created,
comparing bevacizumab+PC to PC alone. Three health states (progression-free survival, progressive disease and death) were
analyzed in a Markov model. The costs were calculated from the Chinese societal perspective. Results were reported in quality-
adjusted life year (QALY) and incremental cost-effectiveness ratios (ICERs).
Results: Bevacizumab+PC came at an ICER of $323343.46 per QALY, which are much more than the accepted willingness-to-
pay (WTP) threshold of $23970.00 per QALY in China.
Conclusions: Addition of bevacizumab to PC is not a cost-effective first-line treatment for MPM when compared with PC in
China.
Biography
Mei Zhan has graduated from Sichuan University and currently working as a Clinical Pharmacist in West China Hospital of Sichuan University. She has published
more than 17 papers in journals of repute.